相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Laura Cortesi et al.
TARGETED ONCOLOGY (2021)
Structural basis of homologous recombination
Yueru Sun et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolism
Magdolna Szanto et al.
GENES & DEVELOPMENT (2020)
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
Xin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma
Siddhartha Yadav et al.
CLINICAL CANCER RESEARCH (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
Joshua James Gruber et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The Role of PARPs in Inflammation-And Metabolic-Related Diseases: Molecular Mechanisms and Beyond
Yueshuang Ke et al.
CELLS (2019)
The Tumor Suppressor PALB2: Inside Out
Mandy Ducy et al.
TRENDS IN BIOCHEMICAL SCIENCES (2019)
Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation
Erika Hamilton et al.
CANCER RESEARCH (2019)
Provider Discussions of Genetic Tests With US Women at Risk for a BRCA Mutation
Leland E. Hull et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2018)
Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome
Josephine Shaw et al.
PATIENT EDUCATION AND COUNSELING (2018)
VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes
Andrew Tutt et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A qualitative study of barriers to genetic counseling and potential for mobile technology education among women with ovarian cancer
Rachel Isaksson Vogel et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2018)
The Role of PALB2 in the DNA Damage Response and Cancer Predisposition
Thales C. Nepomuceno et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease
Karim Gariani et al.
JOURNAL OF HEPATOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Single-Molecule Imaging Reveals How Mre11-Rad50-Nbs1 Initiates DNA Break Repair
Logan R. Myler et al.
MOLECULAR CELL (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tracking the dissemination of a culturally targeted brochure to promote awareness of hereditary breast and ovarian cancer among Black women
Courtney Lynam Scherr et al.
PATIENT EDUCATION AND COUNSELING (2017)
Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study
Tarsha Jones et al.
CANCER MEDICINE (2017)
Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review
Katie E. J. Hann et al.
BMC PUBLIC HEALTH (2017)
Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening
S. Paluch-Shimon et al.
ANNALS OF ONCOLOGY (2016)
ATM kinase: Much more than a DNA damage responsive protein
Ayushi Guleria et al.
DNA REPAIR (2016)
Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk
Monica Marabelli et al.
GENETIC EPIDEMIOLOGY (2016)
The Fanconi anaemia pathway: newyplayers and new functions
Raphael Ceccaldi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist et al.
JAMA ONCOLOGY (2016)
Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer
Nimmi S. Kapoor et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
ATM-dependent Phosphorylation of the Fanconi Anemia Protein PALB2 Promotes the DNA Damage Response
Yingying Guo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Rohit Prakash et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2015)
Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment
Andrea Desmond et al.
JAMA ONCOLOGY (2015)
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
Gwenola Manic et al.
MOLECULAR & CELLULAR ONCOLOGY (2015)
Predictive biomarkers for cancer therapy with PARP inhibitors
J. Michels et al.
ONCOGENE (2014)
Molecular genetic testing and the future of clinical genomics
Sara Huston Katsanis et al.
NATURE REVIEWS GENETICS (2013)
The ATM signaling network in development and disease
Travis H. Stracker et al.
Frontiers in Genetics (2013)
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
Lenka Oplustilova et al.
CELL CYCLE (2012)
Playing the End Game: DNA Double-Strand Break Repair Pathway Choice
J. Ross Chapman et al.
MOLECULAR CELL (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer
Cezary Cybulski et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The DNA Damage Response: Making It Safe to Play with Knives
Alberto Ciccia et al.
MOLECULAR CELL (2010)
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination
Remi Buisson et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2
Eloiese Dray et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints
Zhongsheng You et al.
TRENDS IN CELL BIOLOGY (2010)
Structural basis for recruitment of BRCA2 by PALB2
Antony W. Oliver et al.
EMBO REPORTS (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Sian Jones et al.
SCIENCE (2009)
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage
Shuhei Matsuoka et al.
SCIENCE (2007)
TopBP1 activates the ATR-ATRIP complex
A Kumagai et al.
CELL (2006)
Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage
J Falck et al.
NATURE (2005)
Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex
JH Lee et al.
SCIENCE (2004)
CHEK2 is a multiorgan cancer susceptibility gene
C Cybulski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Provision of genetic services in Europe:: current practices and issues
B Godard et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2003)
分享论文
